AgomAb Therapeutics (NASDAQ:AGMB) Trading 5.1% Higher – Should You Buy?

AgomAb Therapeutics NV (NASDAQ:AGMB) was up 5.1% during trading on Tuesday . The stock traded as high as $13.60 and last traded at $13.84. 154,661 shares changed hands during trading, an increase of 18% from the average daily volume of 131,241 shares. The stock had previously closed at $13.17.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Wall Street Zen lowered shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. HC Wainwright assumed coverage on shares of AgomAb Therapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $35.00 price target on the stock. B. Riley Financial initiated coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target on the stock. Cantor Fitzgerald initiated coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They issued an “overweight” rating for the company. Finally, Piper Sandler assumed coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 target price on the stock. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $37.50.

AgomAb Therapeutics Trading Up 3.1%

The business has a fifty day simple moving average of $13.23.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. As a group, analysts anticipate that AgomAb Therapeutics NV will post -1.76 EPS for the current fiscal year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.